Skip to content

Regional Anaesthesia for Painful Injuries After Disasters

Regional Anaesthesia for Painful Injuries After Disasters (RAPID) Study: A Randomized Trial

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02698228
Acronym
RAPID
Enrollment
0
Registered
2016-03-03
Start date
2016-03-31
Completion date
2018-05-31
Last updated
2017-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture, Lower Limb Injuries

Keywords

anesthesia

Brief summary

The goal of the RAPID study is to fundamentally transform the way serious injuries are managed after earthquakes and other disasters by introducing a novel and cost-effective method for pain control. The study will enroll patients in the aftermath of a major earthquake to determine whether regional anesthesia, either with or without ultrasound-guidance, can reduce suffering from lower limb injuries, the most common earthquake-related injury, above and beyond the current standard of care for pain control in these settings.

Detailed description

The Regional Anaesthesia for Painful Injuries after Disasters (RAPID) study aims to evaluate whether regional anesthesia (RA), either with or without ultrasound (US) guidance, can reduce pain from earthquake-related lower limb injuries in a disaster setting. The proposed study is a blinded, randomized controlled trial among earthquake victims with serious lower extremity injuries in a resource-limited setting. After obtaining informed consent, study participants will be randomized in a 1:1:1 allocation to either: standard care (parenteral morphine at 0.1 mg/kg); standard care plus a landmark-guided fascia iliaca compartment block (FICB); or standard care plus an US-guided femoral nerve block. General practice humanitarian response providers who have undergone a focused training in RA will perform nerve blocks with 20 ml of 0.5% levobupivacaine. US sham activities will be used in the standard care and FICB arms and a normal saline injection will be given to the control group to blind both participants and non-research team providers. The primary outcome measure will be the summed pain intensity difference calculated using a standard 11-point numerical rating scale reported by patients over 24-hours of follow-up. Secondary outcome measures will include overall analgesic requirements, adverse events and participant satisfaction.

Interventions

DRUGBupivacaine (femoral nerve block)

0.5% bupivacaine

DRUGMorphine

Intravenous injection of 0.1mg/kg of morphine

DEVICEUltrasound

Sponsors

Brown University
CollaboratorOTHER
Medecins Sans Frontieres, Netherlands
CollaboratorOTHER
Epicentre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (18 years or older) presenting to an MSF field hospital with one or more lower limb injuries .

Exclusion criteria

* multi-system trauma * severe respiratory distress * hypotension * altered mental status * active infection at the sight of injection * known current pregnancy * unable to provide informed consent. * known allergies to local anesthetic agents or narcotic pain medication * receiving antithrombotic therapy or with a preexisting coagulopathy * likely to receive regional anesthesia for alternative reasons within two hours of screening

Design outcomes

Primary

MeasureTime frameDescription
Pain intensity24 hoursThe summed pain intensity difference (SPID), a widely used measure for assessing the efficacy of new methods for pain management will be administered before and 24 hours for all patients.

Secondary

MeasureTime frameDescription
Analgesic requirements24 hoursAnalgesic requirements will be recorded as the total amount of analgesic medication received during the full 24 hours of patient follow up.
Patient satisfaction24 hoursAll patients will be assessed at 24 hours for their overall satisfaction with their pain management on a standard Likert scale
Serious Adverse Events24 hoursThe investigators will monitor all patients for serious adverse events, including allergic reaction or local anesthetic systemic toxicity (LAST) from the regional anesthesia or respiratory depression or hypotension from narcotic pain medications

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026